Contact
searchSearch
HMP Global
Login

Follicular Lymphoma Resource Center

FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
From Oncology
News
Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma
01/15/2024
Jordan Kadish
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene...
01/15/2024
Oncology
From Oncology
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
News
Yttrium-90 Ibritumomab Tiuxetan Among Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma
05/17/2022
Ellen Kurek
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life...
05/17/2022
Journal of Clinical Pathways
John Burke, MD
Videos
Analysis of Online Treatment Decision Tool Reveals Variation in FL Management Between Experts and Oncology HCPs
03/22/2022
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses...
03/22/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Matthew Matasar, MD
Videos
Health Care Resource Utilization and Costs Among Patients With FL Receiving Multiple Lines of Therapy
12/15/2021
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses...
12/15/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Obinutuzumab for the Treatment of FL
09/23/2021
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the...
09/23/2021
Journal of Clinical Pathways
News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
05/06/2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of...
05/06/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for B-Cell Lymphomas
NCCN Updates Clinical Practice Guideline for B-Cell Lymphomas
03/17/2021
Janelle Bradley
The National Comprehensive Cancer Network update of these guidelines covers follicular lymphoma.
The National Comprehensive Cancer Network update of these guidelines covers follicular lymphoma.
The National Comprehensive...
03/17/2021
Journal of Clinical Pathways
Quiz
Quiz: Does Rituximab Added to Chemotherapy Improve PFS and OS in FL?
12/17/2020
12/17/2020
Journal of Clinical Pathways

Expert Insights

Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
John Burke, MD
Videos
Analysis of Online Treatment Decision Tool Reveals Variation in FL Management Between Experts and Oncology HCPs
03/22/2022
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses results from a study assessing self-reported practice trends from HCPs using an online treatment decision support tool and compared them with corresponding treatment recommendations from FL experts.
John Burke, MD, discusses...
03/22/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Matthew Matasar, MD
Videos
Health Care Resource Utilization and Costs Among Patients With FL Receiving Multiple Lines of Therapy
12/15/2021
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses...
12/15/2021
Journal of Clinical Pathways
Study Highlights Need to Minimize Health Care Costs in FL
Videos
Study Highlights Need to Minimize Health Care Costs in FL
11/29/2020
Nathan Fowler, MD, MD Anderson Cancer Center, discusses results from a study which explored treatment patterns and health care costs in commercially insured patients with FL.
Nathan Fowler, MD, MD Anderson Cancer Center, discusses results from a study which explored treatment patterns and health care costs in commercially insured patients with FL.
Nathan Fowler, MD, MD Anderson...
11/29/2020
Journal of Clinical Pathways
Treatment Options for Patients With Relapsed/Refractory FL
ENGAGING EXPERTS
Treatment Options for Patients With Relapsed/Refractory FL
10/15/2020
10/15/2020
Journal of Clinical Pathways
Assessing Response to Follicular Lymphoma Treatment
ENGAGING EXPERTS
Assessing Response to Follicular Lymphoma Treatment
09/24/2020
09/24/2020
Journal of Clinical Pathways
Headshots
Interview
Endometrial Cancer Risk Research Suggests Earlier Intervention Across Age Groups
09/17/2025
Mengmeng Du, ScD, MSc; Noah C. Peeri, PhD, MPH
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer epidemiologists share their findings on endometrial cancer risk in younger women, highlighting the powerful role of obesity and metabolic health, shared risk patterns across age groups, and the importance of...
In this interview, guest cancer...
09/17/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Second Opinions in Oncology: Quality, Communication, and Patient Confidence
09/16/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down Health Care, John Hennessy and Dr Michael Kolodziej explore the many dimensions of second opinions in oncology—ranging from in-practice consultations to academic referrals, payer-sponsored programs, and...
In this episode of Breaking Down...
09/16/2025
Cancer Care Business Exchange
Golla Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
09/10/2025
Vishnukamal Golla, MD, MPH
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal Golla, vice president of clinical technology and performance at Evolent Health, shares how the Predictable Cost of Care model shifts the focus from drug acquisition costs to a comprehensive view of total care...
In this discussion, Dr Kamal...
09/10/2025
Journal of Clinical Pathways
Thawani Headshot
Videos
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
08/28/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
08/28/2025
Journal of Clinical Pathways
Blog
CPC+CBEx 2025 Abstracts: Business Models, Breakthrough Tools, and Data-Driven Decisions Driving the Future of Cancer Care
08/27/2025
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5-6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into...
The 2025 Clinical Pathways...
08/27/2025
Journal of Clinical Pathways
Wilfong Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/20/2025
Lalan Wilfong, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/20/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Developing a National Pathway Framework for Prostate Cancer: Insights From Solaris Health
08/15/2025
Jason Hafron, MD
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how Solaris Health developed and implemented standardized, National Comprehensive Cancer Network (NCCN)-based prostate cancer pathways across its national network to ensure consistent, high-quality care, streamline...
Jason Hafron, MD, discusses how...
08/15/2025
Journal of Clinical Pathways
Jennifer Woyach, MD
Interview
Overcoming Resistance to Targeted Therapies in CLL Through Personalized Treatment Approaches
08/13/2025
Jennifer Ann Woyach, MD
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores how emerging resistance mechanisms to Bruton tyrosine kinase (BTK) and BCL2 inhibitors are reshaping personalized treatment strategies and diagnostic workflows in chronic lymphocytic leukemia (CLL).
This expert interview explores...
08/13/2025
Journal of Clinical Pathways
Henschel
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/13/2025
Rhonda Henschel, MBA
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/13/2025
Journal of Clinical Pathways
Arrowsmith Headshot
Videos
Driving Change: What the PCC Working Group Has Learned and What’s Next
08/08/2025
Edward Arrowsmith, MD
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care Working Group (the PCC) is a multi-organizational effort comprised of pharmaceutical and biotech manufacturers, pathway vendor organizations, community practices, IDNs, and payers. The purpose of the PCC is to...
The Predictable Cost of Care...
08/08/2025
Journal of Clinical Pathways

Newsfeed

FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
News
Value of MAP Signature and M7-FLIPI for Identifying Risk and Outcomes for Patients With Follicular Lymphoma
01/15/2024
Jordan Kadish
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...
Identifying specific gene...
01/15/2024
Oncology
News
Yttrium-90 Ibritumomab Tiuxetan Among Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma
05/17/2022
Ellen Kurek
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life follow-up in a recent retrospective study, single-agent (90)Y-IT may be highly efficacious with durable long-term survival in previously untreated low-grade follicular lymphoma and marginal zone lymphoma...
According to the long real-life...
05/17/2022
Journal of Clinical Pathways
News
Obinutuzumab Cost-Effective vs Rituximab Biosimilars for Previously Untreated FL
05/06/2021
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of FL, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy in the United States.
For the first-line treatment of...
05/06/2021
Journal of Clinical Pathways
Conference Coverage
Rituximab Monotherapy Extends TTNT vs Observation in Advanced FL
12/11/2020
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Rituximab monotherapy improves...
12/11/2020
Journal of Clinical Pathways
News
HHS Final Rule Expands Real-Time Prescription Access, Eases Prior Authorization Burdens
09/26/2025
Grace Taylor, MS, MA
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of Health and Human Services (HHS) rule taking effect October 1 will give doctors and patients real-time access to drug costs and prior authorization decisions.
A sweeping new US Department of...
09/26/2025
Journal of Clinical Pathways
Conference Coverage
Real-World Evidence in Oncology: Opportunities, Challenges, and Clinical Impact
09/10/2025
Grace Taylor, MS, MA
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session, experts debate how real-world evidence can complement clinical trials, accelerate regulatory approvals, and reshape patient care.
In this CPC+CBEx session,...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Building a Transparent Framework for Predictable Cost of Care in Oncology Pathways
09/10/2025
Hannah Musick
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care initiative is creating a transparent, standardized model to quantify the true, incremental costs of cancer therapies—enabling more informed, equitable, and efficient decision-making across pathways, payers, and...
The Predictable Cost of Care...
09/10/2025
Journal of Clinical Pathways
Conference Coverage
Reviewing a Decade of Oncology Pathways: Standardization, Gaps, and the Road to Real-Time Intelligence
09/09/2025
Hannah Musick
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American Society of Clinical Oncology’s (ASCO’s) original guidance, oncology pathways are maturing into powerful tools for standardizing care, but gaps in disease coverage, workflow integration, and real-time adaptability...
A decade after the American...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
AI as a Thought Partner: Reframing Innovation in Medicine and Practice Management
09/09/2025
Grace Taylor, MS, MA
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx, experts explore how artificial intelligence (AI) is emerging as a “thought partner” in health care, helping clinicians and practices manage rising complexity and improve outcomes while preserving the human touch...
In this panel from CPC+CBEx,...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
How AI is Reshaping Clinical Practice, Governance, and Patient Trust
09/09/2025
Grace Taylor, MS, MA
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation to reshaping prior authorization, a panel of experts reveal how artificial intelligence (AI) is changing the realities of cancer care—and the challenges that come with it.
From streamlining documentation...
09/09/2025
Journal of Clinical Pathways
Conference Coverage
From Dispensing to Decision-Making: How Pharmacists Are Redefining Leadership in Oncology Care
09/08/2025
Grace Taylor, MS, MA
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how pharmacists are stepping into pivotal leadership roles, balancing science, business, and patient care to navigate the increasingly complex oncology treatment landscape.
This session highlights how...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Theranostics: Clinical Promise, Operational Hurdles, and the Road Ahead
09/08/2025
Hannah Musick
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging as a transformative, fifth pillar of cancer care—combining precision imaging and targeted radiopharmaceutical therapy—but its widespread adoption hinges on overcoming operational, financial, and infrastructure...
Theranostics is rapidly emerging...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Scaling Bispecifics and CAR T-Cell Therapy in Community Oncology: From Promise to Practice
09/08/2025
Hannah Musick
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders urged community practices to take immediate, systematized steps to adopt bispecifics and CAR T-cell therapies—highlighting that without local access, the promise of these innovations may never reach the patients...
A panel of oncology leaders...
09/08/2025
Journal of Clinical Pathways
Conference Coverage
Practical Insights for Embedding Whole-Person Care into Clinical Pathways
09/08/2025
Juliet Gallagher
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025 highlighted how structured triage, real-time care coordination, and non-clinical staff training can transform symptom management and reduce unnecessary acute care utilization in oncology.
A session at CPC+CBEx 2025...
09/08/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost-Effectiveness of Obinutuzumab for the Treatment of FL
09/23/2021
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the first-line treatment of follicular lymphoma, obinutuzumab plus chemotherapy is cost-effective in comparison with rituximab biosimilars plus chemotherapy.
True or False: For the...
09/23/2021
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use